Given the clinical interest in developing and enhancing Treg therapies for GVHD, we evaluated whether Treg-specific ACC1 deletion would increase the ability of Tregs to prevent acute GVHD (aGVHD). The gene discussed is ACACA; the disease is graft versus host disease.